Glaucoma Clinical Trial
Official title:
Non-inferiority of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Patients With Open-angle Glaucoma or Ocular Hypertension
Verified date | January 2023 |
Source | Nanodropper, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the effect of microdrops vs. standard eyedrops of 0.5% timolol maleate in adults with primary open-angle glaucoma or ocular hypertension in terms of intraocular pressure-lowering efficacy and cardiovascular side effects.
Status | Completed |
Enrollment | 420 |
Est. completion date | December 19, 2022 |
Est. primary completion date | December 19, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - =18 years old - Recent diagnosis of primary OAG or OHT - Treatment-naive (not currently using ophthalmic medication) - Baseline IOP between 21-35 mm Hg - Corrected Snellen visual acuity of 6/60 or better in each eye Exclusion Criteria: - <18 years old - A recent history (within the past 6 months) of ocular trauma, infection, or uveitis - Baseline IOP <21 mm Hg or >35 mm Hg - History of cardiovascular, pulmonary, cerebrovascular, or chronic renal disease - History of borderline or uncontrolled systemic arterial hypertension - Use of any systemic a-agonist or ß-blocker within 30 days of study commencement - History of receiving general anesthesia within the previous 30 days - Pregnant women and nursing mothers |
Country | Name | City | State |
---|---|---|---|
India | Aravind Eye Hospital | Madurai | |
India | Aravind Eye Hospital | Pondicherry |
Lead Sponsor | Collaborator |
---|---|
Nanodropper, Inc. | Aravind Eye Care System |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intraocular pressure (mm Hg) | 1 hour after drug administration | ||
Primary | Intraocular pressure (mm Hg) | 2 hours after drug administration | ||
Primary | Intraocular pressure (mm Hg) | 5 hours after drug administration | ||
Primary | Intraocular pressure (mm Hg) | 8 hours after drug administration | ||
Secondary | Resting heart rate (bpm) | 1 hour after drug administration | ||
Secondary | Resting heart rate (bpm) | 2 hours after drug administration | ||
Secondary | Resting heart rate (bpm) | 5 hours after drug administration | ||
Secondary | Resting heart rate (bpm) | 8 hours after drug administration | ||
Secondary | Resting systolic and diastolic blood pressure (mm Hg) | 1 hour after drug administration | ||
Secondary | Resting systolic and diastolic blood pressure (mm Hg) | 2 hours after drug administration | ||
Secondary | Resting systolic and diastolic blood pressure (mm Hg) | 5 hours after drug administration | ||
Secondary | Resting systolic and diastolic blood pressure (mm Hg) | 8 hours after drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A |